This study explored the function and possible mechanism of bone morphogenetic protein-2 (BMP-2) in the healing of injured peripheral nerves in vivo. Rabbit facial nerves were injured by clamping and then treated with recombinant human BMP-2 (rhBMP-2) or phosphate-buffered saline (control) by injecting once during surgery and twice a day post-injury for 7 days. Facial nerve fragments within 5 mm of the clamping point were examined at different times post-surgery. Axon structures visualized by Bielschowsky staining were similar in experimental and control nerves 2 and 6 weeks post-injury. At 4 weeks post-injury, cross-section images of facial nerves showed that axons treated with rhBMP-2 were denser and thicker, and levels of tau protein were increased. It is concluded from these data that rhBMP-2 may affect injured facial nerve regeneration by inducing more neurons to return to embryonic patterns of tau gene expression.
Introduction
Traumatic peripheral facial palsy (TPFP) occurs commonly after facial nerve injuries due to the increasing number of motor vehicle accidents, personal injury collisions and bullet wounds. 1 The development of microsurgical nerve repair techniques has improved the treatment of complete facial nerve severing, but the recovery of facial nerve function is still unsatisfactory in some TPFP patients. 1 The mechanisms underlying this are unclear; however, histological examination of damaged facial nerves has revealed simultaneous degeneration and regeneration processes and intraneural scar formation. 2 It is necessary to understand more deeply the interplay between axonal regeneration and local growth factors in order to aid the development of new drugs and methods that will improve nerve regeneration.
Bone morphogenetic proteins (BMPs) are a class of acidic peptides that can induce *G Wu and L Zhu contributed equally to this work as joint first authors. G Wu, L Zhu, T Jin et al. rhBMP-2 increases axonal regeneration ectopic cartilage and bone formation. 3 They are a family of cytokines secreted by a variety of tissues and cells, playing important roles in mesoderm induction, limb and tooth development, haematopoietic cell formation and growth factor gene regulation. 4 BMPs have been found to be closely related to the early development of the nervous system and are involved in multiple stages of central nervous system development, 5,6 with some functioning as neurotrophic factors. 7 Studies have also revealed that members of the BMP family are involved in neuronal survival and axonal regeneration processes after nerve injury and that they interact with many other cytokines. 8 It has previously been observed that BMP-2 promotes facial nerve regeneration in vivo. 9 The present study was designed to analyse the possible mechanism of this effect, with reference to the role of microtubuleassociated proteins (MAPs), such as tau, in axonal growth. While axons are clearly able to regenerate without tau, those containing tau appear to regenerate more quickly. 10 Thus, we wanted to test the hypothesis that BMP-2 might affect nerve regeneration by inducing more neurons to return to embryonic patterns of tau gene expression. 11 
Materials and methods ANIMALS

OSTEOGENIC ACTIVITY OF RHBMP-2
Recombinant human BMP-2 (rhBMP-2; kindly provided by the Laboratory of Molecular Biology, The Fourth Military Medical University, Xi-an, China) was evaluated for osteogenic activity. Briefly, 100 µg rhBMP-2 was injected intramuscularly (IM) into a mouse thigh. After 7 days the mouse was sacrificed, and skeletal muscle was obtained and stained with haematoxylin and eosin. The presence of cartilage cells in the muscle tissue demonstrated activity of the rhBMP.
TRAUMA MODEL
Rabbits were anaesthetized intravenously (IV) with 3% sodium pentobarbital. Both left and right facial nerve buccal trunks corresponding to the pupil of the animal were exposed by surgery and clamped with a mosquito clamp for 30 s, creating a 1-mm direct damage zone. Intra-and post-operative histology found that axons were pinched off but the epineuria remained intact. Each of the 14 rabbits then received 20 µl of 200 ng/ml rhBMP-2 by microinjection once during surgery at both the near and distal segments of the left facial nerve buccal trunk membrane and, after surgery, 40 µl of 200 ng/ml rhBMP-2 injected IM around the clamping point twice a day for 7 days (experimental treatment). The placebo treatment was similar but with 0.1 M phosphate-buffered saline (PBS), pH 7.2 -7.4, rather than rhBMP-2 injected into the right facial nerve buccal trunk. Clamping points were marked with filaments and wounds were closed layer by layer. Intramuscular antibiotics were given twice, once on the day of surgery and once the day after, in order to prevent infection.
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Facial nerve fragments within 5 mm of the clamping point were collected at 2, 4 and 6 weeks after surgery from four, six and four animals, respectively. The mandibular marginal trunk of the right facial nerve of each animal was taken as the normal control. The nerve fragments were fixed in 10% formalin, paraffin embedded and then sectioned longitudinally and transversely. The neurofibrillaries were stained using Bielschowsky's method 12 and changes in nerve fibres were observed by microscopy. Microscope images of facial nerve crosssections collected 4 weeks after surgery in experimental and control groups were then examined under a microscope connected to a Sony colour digital DXC-S500 camera (Sony Electronics, Oradell, NJ, USA). Images were acquired using Image-Pro ® Express software (Media Cybernetics, Silver Spring, MD, USA). Axonal indices, including density, diameter and cross-sectional area, were measured and statistically analysed.
IMMUNOHISTOCHEMISTRY
The nerve fragment sections were de-waxed and endogenous peroxidase was blocked by immersing the slides in a 3% solution of hydrogen peroxide. After washing with distilled water, slides were heated to boiling point in a microwave for 10 s, then cooled and incubated with antigen retrieval solution for 10 min. After a tap water bath, the sections were covered with non-immune specific goat serum for 10 min before being incubated with mouse antihuman tau-2 protein monoclonal antibody (1:1000 dilution; Sigma, St Louis, MO, USA) overnight at 4°C. For homology of the tau-2 epitope in mammalian species, the monoclonal antihuman antibody has cross reactivity with rabbit tau protein. 13, 14 The sections were washed three times with 0.1 M PBS, pH 7.2 -7.4 and incubated with biotinylated goat antimouse immunoglobulin (Ig)G (biotin goat antimouse IgG, 1:100 dilution; Proteintech Group, Chicago, IL, USA) at 37°C for 20 min. After washing three times with 0.1 M PBS, sections were reacted with streptavidin-biotin complex at 37°C for 20 min and washed again in 0.1 M PBS. For visualization of tau protein diaminobenzidine-hydrogen peroxide solution was added. The sections were further washed with water, stained with haematoxylin and eosin, dehydrated with ethanol, cleared with xylene, sealed with neutral gum and observed under a light microscope. As a negative control, PBS was used in place of primary antibody.
STATISTICAL ANALYSES
The mean ± SD were calculated for each post-injury time point. All analyses were carried out using SAS version 6.09 (SAS Institute Inc., Cary, NC, USA) for Windows ® . The significance of differences was calculated using a paired, two-tailed t-test. To avoid possible sources of bias, all the observational data were made and analysed by separate observers at different research centres who were unaware of the group to which their specimens belonged. A P-value < 0.05 was considered to be significant.
Results
FACIAL NERVE HISTOLOGY
There were no apparent differences in the histological appearance of axons in control and rhBMP-2-treated nerves 2 weeks postinjury. In both groups at 2 weeks post-injury, facial nerve perineuria were compact and thin, myelin sheaths at the clamping points were severely degenerated. There were few axons far from the cell body and axons closer to the cell body were swollen or thinning.
At 4 weeks post-injury in the control group, bead-like swelling and obvious axonal buckling were still seen in the nerve fibres and ambiguous axonal forms were observed with Bielschowsky staining. By contrast, in the rhBMP-2-treated group, bead-like swellings were not obvious, and axonal forms were clear and perpendicularly arranged. Cross sections of axons in the rhBMP-2-treated group were regularly arranged and evenly distributed, whereas those in the control group were chaotic and aggregated in clusters, indicating relatively severe nerve bundle oedema.
At 6 weeks post-injury the facial neural structures of both groups were similar to those of healthy nerves; axonal swelling was not present and nerve fibres were regularly arranged. There was no apparent difference between the rhBMP-2-treated and control groups.
QUANTITATIVE ANALYSIS OF NERVE REGENERATION
Axon number, axon diameter and axon cross-section were significantly greater in the rhBMP-2-treated group than in controls at 4 weeks post-injury (P < 0.05, P < 0.01 and P < 0.01, respectively; Table 1 ).
TAU PROTEIN IMMUNOREACTIVITY
Tau protein staining in cross-sections of facial nerve specimens at 4 weeks postsurgery was largely negative in the control group and largely positive in the rhBMP-2treated group (Fig. 1 ).
Discussion
Bone morphogenic protein was originally identified because of its ability to promote ectopic bone formation, 15 a function that was exploited in the present study to test the activity of rhBMP-2. A series of mainly in vitro studies has shown that a low concentration of BMP promotes axon regeneration either directly or by interacting with other factors. For example, BMP-2 can up-regulate three neurofilament proteins in PC12 cells, 16 it can significantly promote tumour necrosis factorinduced nerve growth factor production in fibroblasts, 17 and can affect axon regeneration by promoting expression of neural cell adhesion molecules. 18 A previous report by Wang et al. 9 showed that BMP-2 can promote in vivo facial nerve regeneration, which was in agreement with a study by Muma et al. 19 For a better understanding of the possible mechanism underlying this effect, the levels of tau protein in injured facial nerve axons were examined in the present study. Tau protein is the most abundant microtubule-associated protein in the brain. 20 Although tau protein is encoded by a single-gene, it has multiple mRNAs due to selective splicing. This results in many tau protein isoforms, which can be classified into two categories: low molecular G Wu, L Zhu, T Jin et al. rhBMP-2 increases axonal regeneration weight tau proteins (50 -65 kDa), present in the central nervous system and highly expressed during embryonic development; and high molecular weight tau proteins (100 -120 kDa), mainly expressed in the mature peripheral nervous system. 21 Due to a high degree of homology, the monoclonal antibody directed against tau protein can recognize the majority of tau isoforms. 22 When peripheral nerves are injured, tau protein and mRNA levels in axons decrease rapidly. 23 After the acute phase of injury, the injured nerve axons regenerate and tau protein levels return to normal levels when axons reach their target organs. 11 During axonal regeneration, tau mRNA is widely expressed, but tau proteins are only present in those axons that regenerate the quickest. 10, 24 Although tau protein is not necessary for nerve regeneration, axons that show an embryonic pattern of MAP gene expression grow more dynamically. 10, 25 The present study exploited autologous facial nerves to analyse the effect of exogenous rhBMP-2 on axon regeneration after nerve injury. Analysis of facial nerve axons showed • Received for publication 6 April 2010 • Accepted subject to revision 16 April 2010 • Revised accepted 11 August 2010 Copyright © 2010 Field House Publishing LLP that rhBMP-2 improved nerve regeneration and up-regulated tau protein. Considering the role of BMP-2 in neural development, we speculate that the exogenous rhBMP-2 induced more axons to up-regulate tau protein, perhaps along with other MAPs and cytoskeleton proteins, returning cells to embryonic patterns of gene expression and, consequently, promoting axon growth.
The present study suggests a link between BMP-2 and tau protein in axon regeneration, but the detailed mechanism remains to be further defined. Additional experiments, such as examining axon regeneration with a tracer at different time points, are required in order fully to elucidate the mechanism. It also remains to be determined whether BMP injection itself directly affects nerve function.
